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1 INTRODUCTION 
The present thesis was part of the project “The physiological relevance of bile 
pigments. In vitro to in vivo evidence of antioxidant, anti-mutagenic and anti-
carcinogenic potential and their mechanisms of action” and funded by the FWF-
Austrian Science Fund. The project was performed at the Department of Nutri-
tional Sciences of the University of Vienna and was furthermore supported by a 
scientific team of the Medical University of Vienna. 
Bile pigments are coloured tetrapyrrols that arise in the liver during heme ca-
tabolism. For a long time especially its main components bilirubin and biliverdin 
were thought to have useless or even toxic properties. However, in particular 
the unconjugated form of bilirubin had come to researchers focus since antioxi-
dative potentials have been reported. Therefore, a lot of in vitro and in vivo stud-
ies have been conducted until now aiming to investigate these actions. A certain 
condition in humans with mildly elevated unconjugated bilirubin levels is the Gil-
bert´s Syndrome. While strongly elevated levels of bilirubin may lead to severe 
neurologic damages, conditions seen in Gilbert´s Syndrome have been sug-
gested to be even protective.  
Oxidative stress may cause increased chromosomal and DNA damage which is 
known as a risk factor for developing cardiovascular disease and cancer. The 
Buccal Micronucleus Cytome Assay exhibits an optimal method for investigating 
chromosomal aberrations like micronuclei, broken eggs or binucleated cells. Not 
fully acknowledged nowadays this minimally invasive method may be predictive 
of risk factors like cancer or exposure to environmental substances on health 
status.  
This study tried to combine these two fields and aimed to investigate the anti-
oxidative properties of bilirubin in humans and their chromosomal protective ef-
fects. The authors’ interest focused on whether unconjugated bilirubin was able 
to prevent from chromosomal and DNA damage.  
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Hence, subjects with Gilbert´s Syndrome and matched healthy controls were 
recruited and their bilirubin concentrations as well as their chromosomal status 
were investigated. 
The authors’ hypothesis was that individuals with Gilbert´s Syndrome show less 
chromosomal damage than controls.  
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2 LITERATURE REVIEW 
 
2.1 BILIRUBIN 
Bilirubin, a yellow coloured molecule sensitive to oxidation and light, is the ulti-
mate breakdown product of hemoglobin. This tetrapyrrole, a principle human 
bile pigment, was thought for a long time to have no physiological function than 
being a waste product of heme catabolism – useless at its best and toxic at its 
worst. Indeed, high concentrations of serum bilirubin may cause irreversible 
damages to the central nervous system, especially in neonates. Nevertheless, 
research of the past 20 years revealed a strong evidence for antioxidant and 
anti-inflammatory potential of bilirubin when blood levels are moderately ele-
vated [Fevery, 2008, Vitek and Schwertner, 2007]. The following chapter fo-
cuses on bilirubin - its chemistry, metabolism, adverse and beneficial effects. 
 
2.1.1 Bilirubin chemistry 
 
 
 
Figure 1: Chemical structure of bilirubin [Fevery, 2008]. 
 
Bile pigments, such as biliverdin (BV) and bilirubin (BR) are produced at a rate 
of about 300 mg per day in human adults as a result of heme breakdown 
[Zunszain et al., 2008]. The natural occurring form of unconjugated bilirubin 
(UCB) is the UCB molecule IXα 4Z, 15Z which is characterized by four pyrrole 
rings that are connected by carbon bridges (Figure 1). Two other isoforms IIIα 
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and XIIIα exist, which are formed by non-enzymatic processes by splitting UCB 
IXα into two halves. The nearly symmetrical and lipophilic UCB molecule is a di-
carboxylic acid containing several polar functional groups [Vitek and Ostrow, 
2009]. 
Determination of the crystal structure and the so-called “ridge-tile”- conformation 
brought new information. The interplanar angle between the dipyrrinone groups 
is about 100°. It allows each of the two acid groups to make three hydrogen 
bonds with the opposite dipyrrinone ring system and is responsible for its poor 
aqueous solubility. Because of its apolar properties bilirubin is strongly associ-
ated with specific proteins for further transportation in body fluids, such as al-
bumin in plasma [Fevery, 2008, Zunszain et al., 2008, Ostrow et al., 1994]. 
The unstable UCB molecule is characterized by quickly oxidized double bonds 
and its high sensitivity to light. Furthermore, bilirubin reacts at low and high pH 
values [Vitek and Ostrow, 2009]. 
 
2.1.2  Bilirubin metabolism 
Bilirubin is the result of hemoglobin catabolism in mammals. Hemoglobin is re-
leased by the breakdown of senescent red blood cells and in this metabolic 
process it is metabolised into free heme and globin. The heme pathway is 
summarized in Figure 2. Heme is reduced to biliverdin IXα by the rate limiting 
enzyme hemeoxygenase-1(HO-1) and one molecule of iron and CO is released. 
Heme can be toxic due to pro-oxidative effects and needs to be eliminated as 
fast as possible from the human body. In addition to HOs important role in heme 
degradation further facts about its possible preventive role were explored [Kim 
et al., 2011].  
Until now, three isoforms of HO (HO-1; HO-2; HO-3) have been identified. HO-1 
is inducible; a lot of components like metals, cytokines, endotoxins, oxidants 
and vaso-active components as well as circumstances like heat shock or other 
forms of intra- or extracellular stress may lead to the enzymes activation. HO-2 
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on the contrary is constitutively expressed. It is mainly located at higher levels in 
the brain and the testes. HO-3 is not expressed in humans and does not have a 
high catalytic activity. Studies show that especially HO-1 has protective effects 
on ischemic diseases, hypertension, atherosclerosis and even diabetes mellitus 
[Kim et al., 2011].  
In a second step biliverdin IXα is degraded to biliverdin IXα by biliverdin reduc-
tase. Bilirubins´ formation takes place in the monocytic macrophages of the 
spleen, in the bone marrow and in hepatic Kupffer cells [Sassa, 2006, Vitek and 
Schwertner, 2007, Fevery, 2008]. 
Every day about 4 mg heme/ kg bodyweight is produced. This amount equates 
to 250-300 mg bilirubin. In neonates more is formed. About 75-80 % of bilirubin 
arises from hemoglobin sources. Further 20-25 % are produced by non-
hemoglobin heme-sources like myoglobin, cytochrome P 450 isoenzymes, cata-
lase, peroxidase and tryptophan pyrrolase, that are primarily located in the liver. 
Conjugated (direct) and unconjugated (indirect) bilirubin (UCB) can be found in 
serum with UCB as the predominant one in healthy human subjects with an 
amount of 96 % [Wang et al., 2006, Vitek and Schwertner, 2007, Fevery, 2008]. 
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Figure 2 Heme pathway [Bosma, 2003]. 
 
For further transportation in the blood stream the non-polar UCB binds to hu-
man serum albumin (HSA) with high affinity. The albumin complex is trans-
ported to the liver where a passive uptake is guaranteed and also an active or-
ganic anion transporter (OATP) is known [Vitek and Ostrow, 2009, Toshinori et 
al., 2000].  
Once reached hepatocytes bilirubin undergoes glucuronidation by conjugation 
with glucuronic acid, glucose or xylose. The lipophilic UCB molecule becomes 
hydrophilic which is important for being excreted into the bile. A crucial role for 
forming bilirubin glucuronides plays the enzyme UDP-glucuronosyl-transferase -
1A1 (UGT1A1) [Fevery, 2008, Shigeki et al., 2002].  
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In the intestinal lumen, conjugated bilirubin is promptly converted to urobilino-
gen and urobilins with support from β-glucuronidases and anaerobic bacteria. 
The molecules are reabsorbed by the intestinal mucosa, undergo enterohepatic 
circulation and a minor part is excreted by the kidneys. Urobilin is finally ex-
creted via feces and contributes to its normal colour [Wang et al., 2006, Shigeki 
et al., 2002, Vitek and Ostrow, 2009]. 
 
2.1.3 Disturbed metabolism  
Highly elevated serum bilirubin concentrations (UCB >20 mg/dL) may cause se-
vere conditions in adults and neonates due to its toxicity. Normal concentrations 
of serum bilirubin add up to a maximum of 17.1 µmol/L (1 mg/dL). If total serum 
bilirubin concentrations exceed a level of 513 µmol/L (>30 mg/dL) the risk of 
developing neurological dysfunctions due to bilirubins brain toxicity is given. 
Bilirubin may trespass tissues and causes yellow colour in sclera and skin 
which is known as jaundice (icterus). In very severe forms UCB may also reach 
the blood brain barrier and if untreated may cause kernicterus. Beside the toxic 
form of hyperbilirubinemia a benign form called Gilbert´s Syndrome is known, 
which gained strong interest in the past decades [Silbernagl and Lang, 2005, 
Burke et al., 2009]. 
 
Pathologic forms of hyperbilirubinemia 
Beside its known antioxidative function bilirubin can also be toxic at high con-
centrations that exceed the normal physiological ranges (>20 mg/dL). Higher 
bilirubin levels may be indicative of certain liver diseases or inherited dysfunc-
tion of bilirubin excretion and physiological outcomes depend strongly on its 
concentrations [Vitek and Schwertner, 2007, Bhutani et al., 2004, Wang et al., 
2006]. 
The prehepatic icterus arises when bilirubin production is increased due to cer-
tain factors like hemolysis, inefficient reproduction of red blood cells or massive 
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blood transfusion. Drug and alcohol abuse as well as poisoning and hepatitis 
may cause damages of the liver. Defects of this organ cause intrahepatic ic-
terus which goes along with the lack of excreting normal amounts of bilirubin. A 
posthepatic icterus is the result of a blocked bile duct, due to gall stones or tu-
mours [Löffler, 2008, Silbernagl and Lang, 2005].  
A physiological icterus can be observed in newborns as a consequence of hy-
perbilirubinemia. This icterus occurs when bilirubin production is elevated based 
on the increased degradation of fetal hemoglobin. A pathological icterus is de-
veloping if this hemolysis increases. Without any treatment elevated bilirubin 
levels lead to damages in certain areas of the brain, also known as kernicterus. 
Treatment can be assured through phototherapy. Irradiation of the newborns at 
wavelengths of 400-500 nm (e.g. overnight) is required in order to break down 
UCB. A second possible treatment is replacement-transfusion [Löffler, 2008, 
Silbernagl and Lang, 2005]. 
 
Crigler-Najjar-Syndrome (CNS) 
CNS is found by a severe malfunction of UDP-glucuronosyltransferase due to a 
mutation of the UGT1A1 gene. The enzyme is completely (or nearly completely) 
absent and elimination of bilirubin is almost impossible and therefore leads, 
when untreated, to fatal symptoms. Two types can be distinguished. Type I is 
autosomal-recessive. Bilirubin levels are very high (>200 mg/dL) due to an ab-
sence of glucuronosyltransferase. Most of the children die of kernicterus before 
completing their first year of life if no liver transplantation was conducted and 
phototherapy failed. Only few cases are known worldwide. Type II is autosom-
ally-dominant, the enzyme activity is reduced to <30 % of healthy subjects with 
plasma levels between 50 and 200 mg/L. Therapy is possible by inducing the 
enzyme with Phenobarbital [Strassburg, 2010b, Mutschler et al., 2007].  
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Benign hyperbilirubinemias 
Dubin-Johnson-Syndrome and Rotor Syndrome (DJS/RS) 
Both very rare disorders are inherited in an autosomal recessive mode. They 
have an elevation of unconjugated as well as conjugated bilirubin in common. 
Standard liver parameters are at normal range but DJS is characterized by a 
black coloured liver as a consequence of the presence of dark lysosomal mela-
nin-like pigments. In Rotor latter cannot be obeyed. However, diagnosis through 
liver biopsy is not recommended. Distinction is warranted by analysis of the 
urine coproporphyrin-I excretion, which is found by 80 % in individuals with DJS 
slightly higher than in subjects with RS (65 %) and therefore serves as a differ-
entiation criterion [Strassburg, 2010b]. 
 
Gilbert´s Syndrome (GS) 
Gilbert´s Syndrome was first described by Gilbert and Lereboulet in 1901 and 
later by Meulengracht and Arias. The syndrome is characterized by mild, 
chronic, nonhemolytic unconjugated hyperbilirubinemia (UCB >17 µmol/L) and 
does not lead to liver inflammation, histological changes or progressive fibrosis 
[Yesilova et al., 2008, Strassburg, 2010a]. 
GS has a prevalence of 5-10 % of the Caucasian population and in general GS 
can be more often found in men than in women (12,4 % and 4,8 %) [Gilbert and 
Lereboulet, 1901, Radu and Atsmon, 2001, Bosma, 2003, Strassburg, 2010b, 
Strassburg, 2010a]. 
Elevated bilirubin levels in people with GS have a 30 % reduction of the normal 
hepatic activity of the enzyme uridine-diphosphate-glucuronosyltransferase 
(UGT1A1). A mutation of the promoter region which is called UGT1A1*28 is de-
scribed and leads to additional TAs in the TATAA box due to a 20 % lowered 
transcription [Bosma, 2003].  
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Because of Gilbert Syndromes harmlessness a correct interpretation of the 
clinical presentation is necessary. Indeed, a higher risk is given when unwar-
ranted invasive diagnostic methods, such as biopsies or endoscopic cholan-
giography, are used. When rightly interpreted, they should be avoided. In litera-
ture conditions as in GS are reported to be protective against cardiovascular 
disease and cancer due to antioxidant actions [Strassburg, 2010a].  
 
2.1.4 Bilirubin – a potent antioxidant?  
For a long time bilirubin was thought only to be a waste product in the human 
metabolism. Decades ago bilirubin was found to have strong antioxidative ca-
pacities. Besides reducing reactive oxygen species (ROS), and therefore oxida-
tive damage, the bile pigment furthermore showed anti-mutagenic, anti-
complementary, anti-inflammatory and anti-viral qualities [Bulmer et al., 2008b]. 
ROS generated by superoxide anion (O2), hydroxyl radical (HO
°) and hydrogen 
peroxide (H2O2) are inter alia contributing to the pathology of cancer, tumour 
promotion, aging, cardiovascular events and chronic inflammation. Prevention 
from oxidation is warranted through endogenous antioxidative enzymes like su-
peroxide dismutase, catalase and glutathione peroxidase and exogenous anti-
oxidants like Vitamins E, C and β-carotene [Stocker, 2004, Stocker et al., 
1987b]. 
Bilirubin also plays a main role in oxidant defence due to H-donation to radicals. 
Therefore, the bile pigment is known for preventing oxidation of fatty acids, 
scavenging singlet oxygen, reducing peroxyl radicals and protecting human LDL 
from oxidation. Moreover, studies showed a synergistic effect of bile pigments 
with α-tocopherol in preventing membrane lipid peroxidation because it reduces 
the α-tocopherol radical. [Stocker, 2004, Stocker et al., 1987b]. 
It is demonstrated that UCB is >20 times more effective than Trolox (a Vitamin 
E analogue) on preventing in vitro LDL oxidation after Cu2+ addition. Under de-
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fined conditions 17 µmol/L of UCB inhibits LDL oxidation whereas 500 µM 
Trolox are needed to receive the same results [Wu et al., 1994].  
A former in vitro experiment by Stocker et al., 1987 aimed to measure antioxi-
dant activity of bilirubin when linoleic acid is oxidised to linoleic acid hydroperox-
ide (LOOH) by a free radical chain mechanism. A significantly minor formation 
of LOOH could be observed in presence of low doses of bilirubin and its precur-
sor biliverdin. Moreover a partial inhibition of the chain reaction was achieved 
through bilirubin. Therefore, the bile pigments are assumed to be able of scav-
enging peroxyl radicals [Stocker et al., 1987a]. 
Stocker et al., 2004 also mentioned that it is not clear to what extent bile pig-
ments deploy anti-oxidant activity in vivo. A study by Datla et al., 2007 exam-
ined effects of HO-1 induction on NADPH-oxidase activity in ApoE0 mice and 
authors discovered that HO-1 and bilirubin suppress the enzymes activity which 
reduces oxidative stress.  
Furthermore Sedlak et al., 2009 showed an increased lipid oxidation in HO-2 
knockout-mice which goes along with a higher risk for neurotoxic damage and 
stroke because of reduced bilirubin levels [Sedlak et al., 2009]  
Because of bilirubins´ antioxidative properties Mc Carty, M., 2007 hypothesizes 
that vascular as well as cancer risk may be reduced by donating HO-1 inducers, 
bilirubin or biliverdin supplements or drugs that are able to decrease hepatic 
bilirubin conjugation (e.g.: Probenecid). The efficacy of Probenecid which is 
known as well-tolerated and the use of phycobilins originating from plants, algae 
and cyanobacteria may decrease UGT1A1 and elevate UCB levels. Phycobilins 
show comparable antioxidative qualities as bilirubin and may therefore be inter-
esting for being used for therapeutically measures [Mc Carty, 2007]. 
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Bilirubin and cardiovascular disease 
The antioxidative properties of UCB are assumed to reduce the risk for CVD. 
Vitek et al., 2002 investigated whether elevated bilirubin levels have positive ef-
fects on ischemic heart disease (IHD). Results showed a significantly lower 
prevalence of IHD in GS subjects (2 %) compared to the general population 
(12.1 %). Furthermore the total antioxidative capacity as well as HDL choles-
terol was higher in GS subjects than controls. A protective role against develop-
ing IHD resulting from mild chronic hyperbilirubinemia (>17 µmol/L UCB) is as-
sumed [Vitek et al., 2002]. 
Reduced risk for CVD has also been noticed in individuals with GS by Bulmer et 
al., 2008. Blood samples from subjects with GS and controls were determined 
for antioxidant status measuring. FRAP, TEAC, MDA, SOD, GPx, CAT and 
Cu2+ induced serum oxidation was evaluated. An increased lag phase of serum 
oxidation (p= 0.020) in comparison to the controls was assessed, showing a 
higher antioxidative capacity. Moreover, a trend for an elevated HDL: LDL ratio 
was found in the GS group (p= 0.072). These biomarker based results suggest 
a decreased prevalence for CVD in individuals with GS [Bulmer et al., 2008a]. 
A recent study by Yoshino et al., 2011 aimed to investigate the influence of se-
rum bilirubin concentration on coronary endothelial function in overweight sub-
jects. 107 patients without coronary artery disease were divided into an over-
weight (BMI  25 kg/m2) and a normal weight group (BMI <25 kg/m2). Beside 
estimation of serum total bilirubin, direct bilirubin, LDL-C, HDL-C and triglyc-
erides were measured. The coronary vasoreactivity was measured by flow-
mediated dilatation (% FMD). In the overweight group total bilirubin was signifi-
cantly associated with % FMD (p <0.05) and HDL-C (p <0.05). These correla-
tions could not be found in normal weight subjects and leads to the assumption 
that elevated bilirubin levels support endothelial function in overweight patients 
[Yoshino et al., 2011].  
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Bilirubin and cancer 
In vivo studies 
The association between serum bilirubin and cardiovascular and cancer mortal-
ity was investigated by Temme, et al., 2001. Data from 5460 men and 4843 
women aged between 25 and 74 years were collected and analyzed in the Bel-
gium Inter-university Research on Nutrition and Health (BIRNH) study. A base-
line survey focusing on the relationship between diet and mortality was firstly 
conducted between 1981 and 1984. Ten years after the first data collection 
each subject was ascertained for vital status and cause of death. Average se-
rum bilirubin levels were higher in men (0.44 mg/dL) compared to women (0.35 
mg/dL). Results showed that men with higher serum bilirubin levels had a 58 % 
reduced risk of cancer mortality. The same trend was seen in women, who had 
a 24 % reduced risk, but no statistic significance could be established [Temme 
et al., 2001].  
An epidemiological study conducted by Zucker et al., 2004 aimed to determine 
serum bilirubin levels of 16,865 subjects representing the U.S. population. 
Therefore, data of the Third National Health and Nutrition Examination Survey 
(NHANES III) collected between 1988 and 1994 were analysed. Men showed 
significantly higher UCB concentrations than women (p <0.001). Results 
showed a significant inverse relationship between serum bilirubin concentra-
tions and the incidence of colorectal cancer. A noticeable decrease in preva-
lence of colorectal cancer can be associated with an increase of each 1 mg/dL 
in serum bilirubin. Even though no classification in direct or indirect fractions 
was done the authors presume that preventive effects are resulting from the lat-
ter. Prevention from gastrointestinal malignancy by bilirubin can be assumed 
[Zucker et al., 2004]. 
Horsfall et al., 2011 examined the association between serum bilirubin levels 
and chronic obstructive coronary disease (COPD), lung cancer and all-cause 
mortality in a cohort of 504.206 subjects. Information was provided by The 
Health Improvement Network (THIN), a database from the United Kingdom that 
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includes more than 7 million people. Similar to the previously mentioned studies 
men had higher serum bilirubin levels (0.64 mg/dL) than women (0.53 mg/dL). 
Higher serum bilirubin concentrations were both in men and women associated 
with a decreased risk of lung cancer and all-cause mortality [Horsfall et al., 
2011]. 
 
In vitro studies 
Another study by Rao et al., 2006 investigated bilirubins´ action in human carci-
noma cell lines. The results interestingly showed an antioxidative effect in hepa-
tocytes- as well as pro-oxidative nature in human gastric carcinoma cell lines 
(TMK-1). An increase of ROS and DNA damage leads to coding for yet un-
known apoptotic structures. TMK-1´s growth gets inhibited to nearly 50 %. Even 
if antioxidative effects of bilirubin are more frequent the authors assign anti-
cancer effects due to pro-oxidative actions [Rao et al., 2006]. 
Although, there are plenty of studies that postulate the protective effects of UCB 
in vivo a recent hypothesis by Astolfi, et al., 2011 links decreased UGT1A1 ac-
tion in patients having GS with a higher risk for breast cancer. Inactivation of po-
tentially carcinogenic 4-OH estrogens through the enzyme is lowered; accumu-
lation may lead to a higher risk for developing tumours in breast tissue. Authors 
rely on two studies associating UGT1A1 with a 28 time higher risk for breast 
cancer. However, data evaluating GS and breast cancer risk are rare and fur-
ther investigations in vitro and in vivo are necessary for proving this theory 
[Astolfi et al., 2011].  
The relationship between bile pigments and its anti-mutagenic actions was in-
vestigated by Bulmer et al., 2007 performing the Ames Salmonella test in three 
bacterial strains (TA98, TA100, and TA102). Results admit anti-mutagenic po-
tential to bilirubin and biliverdin in presence of several mutagens (e.g.: TBOOH). 
Arimoto, et al., 1980 who able to show protective effects of hemin, bilirubin and 
biliverdin on mutagenic influences of benzo[α]pyrene [Bulmer et al., 2007].  
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Bilirubin may be seen as a biomarker for CVD and related diseases. So far, the 
role of BR as a biomarker for cancer has not been fully acknowledged although 
epidemiological studies clearly indicated a cancer protective role for BR [Lin et 
al., 2010, Breimer and Mikhailidis, 2011]. 
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2.2 DNA DAMAGE  
DNA underlies permanent hazards because of environmental or cellular proc-
esses. Especially oxidative stress challenges the cells defence and often its im-
plications lead to cancer, neurodegenerative diseases and cardiovascular risk. 
The following chapter highlights factors leading to DNA damage and the most 
popular assessment methods. Moreover, it focuses in particular on the potential 
of “The Micronucleus Cytome Assay” as a tool for monitoring chromosomal and 
DNA defects in different tissues [Jackson and Bartek, 2009, Thomas et al., 
2009].  
 
2.2.1 DNA damage and ROS production 
The DNA, carrier of the human genetic code can be damaged throughout a 
wide range of reasons. Each of the ~1013 cells in the human body receives 
thousands of DNA lesions every day. Impaired or incorrect repair due to 
blocked genome replication and transcription may lead to mutations or genome 
aberrations causing an increased risk for diverse cancers, neurodegenerative or 
cardiovascular diseases. DNA damage arises also by other mechanisms due to 
oxidative stress. Cellular processes, external factors and/or disease states can 
lead to the formation of reactive oxygen species (ROS) that may interact with 
the DNA. On the one hand ROS are released from phagocytes to destroy cells 
infected with virus or bacteria and on the other hand formed by ionizing and ul-
traviolet radiation or potent environmental carcinogens and chemicals in mito-
chondria (Figure 3). Their negative impacts are based on an overload of O2
-, 
HO° or H2O2 and furthermore lead besides genomic alterations to enhanced 
lipid oxidation, protein oxidation and DNA oxidation [Cooke, 2003, Ferguson et 
al., 2006, Jackson and Bartek, 2009]. 
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Figure 3 shows the impact of ROS on DNA and proteins. ROS are generated in mitochondria, scavenging 
systems exist and if mitochondrial DNA functions well damaged proteins get removed and replaced by 
new ones. In more severe cases as seen in Complex IV deficiency expression of additional genes gets 
stimulated to rescue lost functions. Oxidative damage furthermore leads to induction of apoptosis [Jansen-
Dürr and Osiewazc, 2002].  
 
2.2.2 Methods for estimation of DNA damage 
Since oxidative stress and its consequences lead to an increased health risk it 
is necessary to measure the status of DNA damage in humans. Different bio-
markers have been designed for a better mechanistic understanding on DNA 
and chromosomal level. One possibility is measuring DNA lesions such as 8-
OxodG in urine or leukocytes, lymphocytes or mononuclear blood cells after in-
fluence of oxidative stress. These modified DNA bases represent one of the 
most common lesions that are indicative for failed DNA repair. More direct 
methods include measurements in peripheral blood lymphocytes and buccal 
cells. Single gel electrophoresis (COMET assay) provides investigation of DNA 
single or double-strand breaks and other oxidised DNA bases in lymphocytes 
and can be adapted (with concern to some limitations) also in buccal cells. In 
both, lymphocytes and buccal cells chromosomal aberrations as micronuclei 
can be obtained and related to chromosomal damage. This assay already ac-
credited in lymphocytes shows also huge potential as well in buccal tissue for 
determination of chromosomal alterations and is described in the following sec-
tion [Dhillon et al., 2004, Ferguson et al., 2006, Lee and Pfeifer, 2008]. 
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2.2.3 Buccal Micronucleus Cytome Assay (BMcyt) 
The Micronucleus (MN) assay in exfoliated buccal cells has already been used 
since the 1980s. It represents a minimally invasive and useful method for inves-
tigating DNA damage, chromosomal instability, cell death and the regenerative 
capacity of human buccal tissue. Especially in long-term studies impacts of life-
style, nutrition or genotoxine exposure can be easily determined by harvesting 
cells via a toothbrush, subsequent preparation and analysis. Human buccal mu-
cosa is a barrier for potential pathogenic or carcinogenic compounds, and in-
deed, about 90 % of human cancers have their origin in epithelial cells. There-
fore, it seems self-evident that oral epithelial cells represent a perfect tool for 
biomonitoring risk of diverse diseases in vivo [Holland et al., 2008, Thomas et 
al., 2009]. 
By contrast to the cytokinesis-block micronucleus assay (CBMNcyt) which is 
applied in peripheral blood lymphocytes no standardized protocol for the BMcyt 
is available to date. For solving among other topics the issue of unification the 
“Human MicroNucleus project on eXfoLiated buccal cells” (HUMNXL) was 
launched. The projects aim is to refine the assay by strong collaboration with in-
ternational laboratories [Bonassi et al., 2011]. 
Furthermore first approaches for automation of the BMcyt are described by 
Leifert et al., 2011. Laser scanning cytometry (LSC) is suggested to measure 
biomarkers for DNA damage (micronuclei, broken eggs), cytokinesis defects 
(binucleated cells) or cell death (condensed chromatin, karyorrhexis, pyknosis 
and karyolitic cells) following standardized scoring criteria. Automation may con-
tribute to maintaining uniform results [Leifert et al., 2011].  
Compared to the CBMNcyt no blood samples need to be taken for the BMcyt 
and buccal tissue is easily reachable and therefore, the method serves perfectly 
for large biomonitoring studies, especially in pediatric populations. Easy storing 
of samples and low costs favour this method. Since buccal tissue allows imme-
diate assessment of DNA damage no further replication step is required. The 
BMcyt is successful without establishing cell cultures for analysing meta- and in-
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terphase in binucleated lymphocytes. The strong correlation of MN frequency in 
buccal cells with MN frequencies in lymphocytes warrants great potential in 
biomonitoring risks for certain diseases, in the first place for cancer [Holland et 
al., 2008, Bonassi et al., 2011].  
 
2.2.4 The origin of chromosomal damage 
Endpoints and other nuclear anomalies in the BMcyt 
The oral epithelium is built up of four strata, the lamina propria, stratum basale, 
stratum spinosum and a keratinized layer at the surface. Micronuclei can be 
measured in erythrocytes, lymphocytes and exfoliated epithelial cells. They 
mainly descend from chromosome fragments or whole chromosomes which lag 
behind at anaphase during nuclear division. Such displaced chromosomes or 
fragments are eventually enclosed by a nuclear membrane and can be seen af-
ter staining a smaller round part next to the main nucleus [Holland et al., 2008, 
Fenech et al., 2010]. 
MN are firstly expressed in the basal layer, which contains stem cells that may 
undergo genetic changes. After a period of 7-10 days the cells migrate from the 
basal layer to the surface. Daughter cells which may have MN finally reach the 
surface and exfoliate into the buccal cavity. Seldom, some cells get blocked in a 
binucleated stage or form broken eggs (also known as nuclear buds). They rep-
resent biomarkers of defect cytokinesis and gene amplification, respectively. In 
addition to the mentioned ones biomarkers of apoptosis and necrosis (con-
densed chromatin, Karyorrhexis, Pyknosis and Karyolysis) can be observed 
(Figure 4); [Holland et al., 2008].  
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Figure 4: Various cell types that are scored in the BMcyt [Thomas et al., 2009]. 
 
2.2.5 BMcyt and diseases 
Alzheimer 
First ones to perform the BMcyt in patients suffering from Alzheimer´s disease 
(AD) were Thomas et al., 2007. Their aim was to establish whether MNs or 
other parameters reflecting genome damage or cell death could be used as a 
risk marker for the development of the disorder. Results did not show notable 
differences in MN and BE frequency between the AD and control groups. Sig-
nificantly lower frequencies of basal cells, condensed chromatin and karyor-
rhectic cells (all p <0.0001) in AD subjects where found which may be a sign for 
changes in cellular kinetics or structural profile of buccal mucosa. Authors sug-
gest that a combination of basal and karyorrhectic cells as biomarkers along 
with measurement of AD-specific proteins (tau and β-amyloid) might play an 
important role for detecting individuals with increased risk of AD [Thomas et al., 
2007b].  
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Down´s Syndrome 
The BMcyt was used for investigating the impact of ageing in healthy young and 
old subjects and in a young Down´s Syndrome cohort on cell anomaly fre-
quency. Normal ageing accompanied with decreased cell and DNA repair 
mechanisms and further results showed a significant increase of MN (p <0.05, 
average increase +366 %), KR (p <0.001, average increase +439 %), CC (p 
<0.01, average increase +45.8 %), and basal cells (p <0.001, average increase 
+233 %) compared to young controls. In Down´s Syndrome which is character-
ized by premature ageing an even more significant increase in MN, BN and a 
significant decrease in CC, KR, and P in contrast to the healthy young group 
was observed. Therefore, the BMcyt may be seen as an effective method for 
identifying changes of DNA and different cell types while normal and premature 
ageing [Thomas et al., 2007a].  
Cancer 
Dorea, et al., 2012 focused on the appearance of cytological abnormalities in 
patients with oral malignant neoplasms and healthy subjects using the BMcyt. 
Significantly higher occurrence of MN can be seen in cells collected from le-
sions than in cells from intact areas, independently from cancer pre-or absence 
(p <0.0001). Furthermore MN were significantly more frequent in smokers and 
mouthwash users (p <0.0001). Indicators for apoptosis were also measured 
(CC, KR; P), showing a lower frequency in cells from lesions than in cells from 
normal areas and control group. Apoptosis in buccal tissue might be impaired 
due to this kind of cancer. Investigation of cell alterations in the oral cavity using 
the BMcyt was proved as useful [Dórea et al., 2012]. 
In the study from Dey et al. buccal cells of patients with breast carcinoma and 
patients having benign breast lesions were collected. Micronucleus frequency in 
buccal mucosa was significantly higher in those suffering from carcinoma than 
in subjects with benign breast lesions (p <0.001). Performing the BMcyt and es-
pecially scoring MN should therefore serve as an early detection method for 
high risk breast carcinoma cases [Dey et al., 2010]. 
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2.2.6 BMcyt -Life style and exposure 
The micronucleus frequency in hairdressers and controls was assessed by 
Rickes et al., 2010. Since this occupational group is exposed daily to harmful 
chemical substances, such as p-phenylenediamine, hydrogen peroxide or 
thioglycolic acid in colourings and straigtheners it was in the researchers’ inter-
est to determine their impact on DNA damage and chromosomal instability. Re-
sults clearly showed that all parameters (MN, BNC, BE, and the sum of all 
anomalies) are significantly higher in hairdressers (p=0.0001). A higher 
genotoxic load could be observed in hairdressers concluding that their products 
used are harmful for men [Rickes et al., 2010].  
Yadav and Sharma 2008 used the BMcyt for assessing genotoxic effects of low 
frequency electromagnetic radiation emitted by cell phones on humans. For 
regular phone users the number of micronucleated cells was higher compared 
to non-users. A positive correlation between years of exposure and MN fre-
quency was found even though a slight increase of MN could be observed in 
subjects whose exposure exceeds 4 years. A similar study conducted by 
Hintzsche and Stopper, investigated the same issue. In contrary their findings 
did not show increased micronuclei frequency in mobile phone users [Hintzsche 
and Stopper, 2010, Yadav and Sharma, 2008]. 
Drinking water contaminated with arsenic is a risk factor for developing different 
types of cancer. Bartolotta et al., 2011 therefore evaluated MN frequency in an 
exposed rural population and in an urban population in Argentina. The exposed 
group showed a significant increase in MN frequency compared to controls (p= 
0.0005). Hence, determination of cell aberrations in buccal mucosa could be a 
promising method for measuring potential genetic risk through environmental 
contaminants [Bartolotta et al., 2011]. 
Effects of antioxidants on MN frequency have been reviewed by Thomas et al., 
2010 for both lymphocytes and buccal cells. In the latter significant reductions of 
MN frequencies were obtained through supplementation of high doses of folate, 
α-tocopherol or β-carotene in different cohorts [Thomas et al., 2010]. 
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Even though intervention with single micronutrients or their combinations have 
antioxidative and therefore beneficial effects on MN frequency it is necessary to 
investigate effects of endogenous antioxidants, such as bilirubin. Therefore, the 
present thesis investigated the effect of mildly elevated UCB levels on the 
BMcyt in order to investigate chromosomal modifications in subjects with GS.  
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3 MATERIALS AND METHODS 
3.1 Study Design 
The aim of the recent study was to determine whether the antigenotoxic effects 
of bilirubin prevent chromosomal damage in individuals with mildly elevated cir-
culating serum bilirubin (Gilbert Syndrome). The study was conducted in a 
cross-sectional design and was performed over a period of two years. 
Until now only little information about the effects of oxidative DNA damage in 
people with Gilbert Syndrome is available. Out of this reason the study aimed to 
investigate levels of DNA stability in GS and control subjects. 
It was hypothesized that the cells of the buccal tissue from GS subjects would 
be protected from oxidative induced chromosomal damage due to elevated 
bilirubin levels.  
For the screening a small amount of blood was taken from the subjects after the 
patients´ agreement was filled. A questionnaire checked whether the subjects 
met the inclusion criteria (see criteria below). In case the subjects met them, a 
larger blood sample was obtained at the general hospital of Vienna (AKH) and 
the participants were classified in GS and control.  
Participants were advised to fast and only ingest 400 kcal for 24 hours, before 
the second, main blood collection. As a consequence of fasting, serum bilirubin 
levels rise, especially in people with GS [Owens and Sherlock, 1973]. The next 
morning, buccal cells, blood and urine samples were collected. Buccal cells 
were prepared on slides and stored in boxes at the Institute of Cancer Research 
in Vienna. 
A coding system (e.g. GS_01) for first participant) was used to de-identify sub-
jects and assisted in removing bias from the analysis. Researchers were not 
aware whether subjects had high or low serum bilirubin levels. 
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Study population 
 
This study was approved by the Human Ethics Research Committee of the AKH 
(Ref. No. 274/2010). A patient agreement had to be signed by participants. All 
samples were collected from April to September 2010. 
In total 100 subjects, aged between 20 and 80 years, were recruited for the 
study. The participants were identified as GS, based on their serum unconju-
gated bilirubin concentrations >17.1 µmol/L (>1 mg/dL) determined by high per-
formance liquid chromatography (HPLC). For the clinical definition of GS, serum 
liver enzyme activities and blood counts in the normal range were required in 
addition to increased bilirubin levels. 45 participants were diagnosed with GS 
and 39 were then allocated into the control group. For 16 subjects the assign-
ment could not be performed due to unclear bilirubin levels around 1 mg/dL and 
were just included for statistical analysis using bilirubin tertiles. Participants 
were recruited partly by doctors in the AKH and furthermore, by advertisement 
posted in universities, pharmacies or hospitals, as well as on internet platforms 
and in newspapers. 
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Inclusion criteria 
• 20 – 80 years 
• Total serum bilirubin >20.52 µmol/L (>1.2 mg/dL) in GS subjects 
• Unconjugated serum bilirubin >17.1 µmol/L) (>1 mg/dL) in GS subjects 
• Total serum bilirubin <20.52 µmol/L (<1.2mg/dL) in controls 
• Unconjugated serum bilirubin <17.1 µmol/L (<1 mg/dL) in controls 
• Γ-glutamyltranspeptidase in blood <100 IU 
• Alanin-aminotransferase in blood <100 IU 
• Aspartat-aminotransferase in blood <100 IU 
• Moderate physical activity 
 
Exclusion criteria 
• Younger than 20 years and older than 80 years 
• Cardiovascular diseases 
• Hepatitis B/C 
• Any other liver diseases 
• Cholelithiasis 
• Hemolysis 
• Chronic kidney diseases 
• Past or present cancer 
• Diabetes mellitus 
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• Supplementation with antioxidants in the past four weeks before the first 
blood sample 
• Medication that influences liver values (e.g. Probenecid, Rifampicin) 
• People with organ transplants 
• Current smoking (>5 cigarettes per day) 
• Alcohol consumption (>7 drinks per week) 
• Competitive athletes (>10 hours training per week) 
 
 
Figure 5: Distribution of the study population 
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3.2 BMcyt – Equipment 
The accomplishment of this assay for the present study based on the protocol 
of Thomas et al; 2009.  
 
Name Unit Producer 
Tooth brush 
 
Mentadent 
Plastic tubes  50 mL Sarstedt 
Centrifuge cups 1,5 mL Carl Roth GmbH+Co. KG 
Abacteria Pipettes 10 mL Chase 
Slides and coverslips 
 
HD Schientific 
Coplin jars  Biolab 
Table 1: Equipment used for the BMcyt 
 
3.3 Chemicals 
Name Unit Producer 
Physiologic salt solution  0.9 % Sigma- Aldrich 
Ethanol   Merck 
Bidistilled water   
Institute of Cancer Re-
search, MedUni, Vienna 
Chloric acid 5 M Merck 
Schiff's Reagent   Sigma-Aldrich 
Light Green  0,20% Gurr's 
DePex   Merck 
Methanol 80% Carl Roth GmbH+Co. KG 
Table 2: Chemicals used for the BMcyt 
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3.4 Collection of buccal cells 
The subjects were asked to rinse their mouths twice with water before the cell 
collection. This is an important step to remove excess debris. For each subject 
a topped container with 10 mL salt solution has been prepared before the col-
lection. The container was provided with the subject’s code and the date of col-
lection. 
Participants had to rotate a small-headed toothbrush 10 times against the inside 
of their cheek walls in a circular motion. They were advised not to push too 
much while using the toothbrush to avoid potential irritations and bleedings in 
this sensitive area which could impurify the sample. 
The samples from the toothbrush were collected in the salt solution and the 
process was repeated twice on each cheek. 
Subsequently the containers were closed and stored at 4°C until slides were 
prepared. 
 
3.5 Harvesting buccal cells and slide preparation 
The collected cells were put into TV-10 centrifuge tubes and centrifuged for 10 
minutes at 581 g at room temperature. 
The supernatant was removed; about 1 mL of the cell suspension was added 
with 5 mL salt solution. 
A second centrifugation for 10 minutes at 581 g at room temperature followed. 
This procedure was repeated once more. After two washing steps in salt solu-
tion the best results were maintained. Using salt solution warrants inactivation 
of endogenous DNAses and removal of bacteria and cell debris. 
Again the salt solution was added, cell suspension got homogenized for 2-3 
minutes and then centrifuged under the known conditions (duration: 10 minutes, 
581 g; room temperature)  
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3.6 Fixing buccal cells 
After removing the supernatant the samples were displaced with 2-3 mL of 80 
% methanol depending on the number of buccal cells. The samples were then 
stored for fixing at 20°C for 20 minutes.  
120-150 µL of the cell suspension were dropped on precoded microscope slides 
and dried in the air for about 10 minutes before staining. 
 
3.7 Staining for microscopy 
After drying slides were put into Coplin jars containing 5 M HCl for 30 minutes. 
Then they were well rinsed in running tap water. 
For testing the efficacy of the treatment with HCl a negative control slide was 
bathed in distilled water for 30 minutes instead of 5 M HCl. 
Next the drained slides were placed into Coplin jars containing Schiff´s Reagent 
for 90 minutes in a dark environment at room temperature. Since there was no 
separate dark room available the jars were covered with aluminium foil. 
After 90 minutes the reagent was removed. The slides were first washed in run-
ning tap water and afterwards washed in distilled water. 
As a next step slides were immersed in Coplin jars containing 0.2 % (wt/vol) 
light Green. After 20-30 seconds slides were rinsed well in distilled water. 
To blot away any residual moisture the slides were immediately placed verti-
cally. Moreover it is important not to apply any pressure or rub on the cells as 
this may dislodge and damage the cells. For complete drying slides were placed 
under the laboratory hood over night. 
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3.8 Covering the slides  
The completely dried slides were covered with coverslips under a laboratory 
hood. Using gloves is required because organic solvents in the glue (DePex) 
may provoke irritations of the respiratory tract and the skin. Some drops of De-
Pex were placed on the slides by plastic pipette and immediately coated with a 
coverslip. Excess air bubbles were expelled by pressing the coverslip gently. 
Excess DePex got wiped away from the edges with some paper towel. Fur-
thermore it had to be secured that DePex was neither on top of the coverslips 
nor on the coding area.  
Finished slides were placed on a tray to be dried under the laboratory hood 
overnight. After drying slides were stored in special boxes at room temperature 
until evaluation. 
 
3.9 Microscopy 
Slides were scored for chromosomal damage biomarkers under the micro-
scope. Nuclei and micronuclei are stained in magenta whereas the cytoplasm 
appears pale blue/green. In negative controls without 5 M HCl treatment the nu-
clei will not be stained with magenta colour. 
 
3.10 Scoring criteria 
Cells were scored under a transmitted light microscope using a magnification of 
400. In some cases a magnification of 1000 and the use of immersion oil was 
necessary to ensure the best possible examination.  
First the frequency of all cell types in a minimum of 1000 cells was counted and 
following the frequency of DNA damage biomarkers (MN and BE) was scored in 
a minimum of 2000 differentiated cells. The frequencies of the cell types in the 
assay were then calculated as the number of cells per 1000 differentiated cells. 
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3.11 Cell types 
3.11.1  Differentiated cells 
 
Figure 6: Differentiated cell 
Differentiated cells are more angular and flatter than basal cells. Their nucleus 
is round and uniformly stained. This cell type has a smaller nuclear:cytoplasm 
ratio. Apart from the nucleus no other structures containing DNA can be found 
in differentiated cells [Thomas et al., 2009]. 
 
3.11.2  Cells containing Micronuclei (MN)  
  
 
Figure 7: Cells with micronuclei 
In both cell types, basal or differentiated, micronuclei can be obeyed. Out of 
practical reasons MN in basal cells are not getting counted due to the low fre-
quency of this cell type. In cells with MN a main nucleus as well as one or more 
smaller structures called micronuclei can be seen. MN are characterized by a 
round or sometimes oval shape and their size is between 1/3 to 1/6 of that of 
the main nucleus. MN have the same staining intensity and texture as the main 
nucleus. Furthermore the MN must be located within the cytoplasm of the cells. 
MN are indicative for chromosomal damage or fragmentation during nuclear di-
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vision. In buccal mucosa the frequencies for micronucleated cells are usually in 
a range of 0.5-2.5 MN per 1000 cells [Holland et al., 2008]. 
 
3.11.3  Broken Eggs (BE) 
 
Figure 8: Broken Egg 
BE are also called nuclear buds (NBuds) since nuclear material gets eliminated 
by budding [Tolbert et al., 1991]. The so called NBud is still attached to the main 
nucleus and has a similar staining intensity. BE  reach a size of about ¼ to ½ of 
the main nucleus [Nersesyan, 2005].  
 
 
 
 
 
 
 
 
 
 
 
 
35 
3.11.4  Binucleated cells (BNC) 
 
Figure 9: Binucleated cell 
Binucleated cells contain two main nuclei of a similar size which are usually 
very close and may touch each other. BNC show the same morphology as seen 
in normal cells. Until now the significance of this cell type is not known but they 
are probably indicative of failed cytokinesis [Shi and King, 2005]. BNC may also 
be important biomarkers for identifying aneuploidy, which can be observed in 
people suffering from Down´s Syndrome [Thomas et al., 2007a, Thomas and 
Fenech, 2007].  
 
3.11.5  Condensed Chromatin (CC)  
 
Figure 10: Condensed Chromatin 
In buccal cells with condensed chromatin the nucleus shows areas of aggre-
gated chromatin that is visible in striated nuclear patterns. Some areas are 
more intensively stained which is an apparent sign that chromatin aggregates in 
some regions while it gets lost in other areas [Wyllie, 1981]. It is assumed that 
these cells may indicate early stages of apoptosis, but until now this has not 
been proven [Thomas et al., 2009] 
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3.11.6  Karyorrhectic cells (KR) 
 
Figure 11: Karyorrhectic cell 
In contrast to cells with condensed chromatin karyorrhectic cells are distin-
guished by a more extensive nuclear chromatin aggregation. They have a 
densely speckled nuclear pattern due to fragmentation in the late phase of 
apoptosis. So far this was not shown conclusively [Wyllie, 1981, Tolbert et al., 
1991].  
 
3.11.7 Pyknotic cells (P) 
 
Figure 12: Pyknotic cell 
This cell type is characterized by a small shrunken nucleus which is uniformly 
and very intensely stained [Wyllie, 1981, Tolbert et al., 1991]. Usually the nu-
clear diameter averages out 1/3 to 2/3 of the main nucleus´ normal size. Their 
biological significance and the mechanism leading to their formation are not 
known yet but it is assumed that pyknotic cells may be undergoing a unique 
form of apoptosis or necrosis. It is thought that they may represent an alterna-
tive mechanism of nuclear disintegration that is different from the process lead-
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ing to condensed chromatin and karyorrhectic cell death stages [Holland et al., 
2008, Chen, 2006].  
 
3.11.8  Karyolytic cells (KL) 
 
Figure 13: Karyolytic cell 
This cell type represents a very late stage in the cell death process and may be 
indicative of necrosis. The main nucleus does not contain any structures of 
DNA. Due to depletion of DNA no staining via Feulgen is given. The cytoplasm 
as well as the nucleus appears in a slightly green colour. Therefore, the nucleus 
can hardly be seen and due to their ghost-like appearance they are also called 
“ghost cells” in literature [Wyllie, 1981, Tolbert et al., 1991]. 
Condensed chromatin and karyorrhectic cells were recorded in one category 
since even among scientist some uncertainties are discussed.  
The pictures for this section were taken by the author and Alice Petschnig. 
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3.12 Statistical analysis 
Determined data were statistically analyzed using SPSS Statistics 17.0. 
All statistics referring to cell anomaly frequency in the study were reported as 
the number of anomaly per 1000 differentiated cells. 
Normal distribution (ND) was tested in defined groups by using the Kolmogorov-
Smirnov test.  
For normal distributed data T-test was performed to evaluate differences of 
mean in 2 groups and Oneway ANOVA including a post hoc test was conducted 
for more than 2 groups. 
If ND was not given Mann-Whitney-U-Test was performed in 2 groups and. 
Kruskill-Wallis-H-Test including ANOVA post hoc tests were accomplished in 
more than 2 groups.  
For detecting correlations between 2 parameters Pearson coefficient (ND) or 
Spearman´s rho (not ND) was used.  
A level of p <0.05 was considered significant and marked with *. 
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4 RESULTS AND DISCUSSION 
The aim of the present study was to investigate the relationship between 
bilirubin concentration and DNA damage. Furthermore, it was of high interest 
whether subjects with Gilbert´s syndrome and therefore mildly elevated bilirubin 
levels show less signs of DNA damage compared to control subjects. 
100 individuals participated in the study; general criteria of the study population 
can be seen in Table 3. After the parameters for each individual have been 
counted, statistical analysis was carried out. Results are to be presented in this 
section. 
 Gilbert´s Syndrome Controls Not defineable 
Number 45 39 16 
Men 35 23 12 
Women 10 16 4 
Age (years) 33  13 32  12 26  6 
UCB (mg/dL) 1.9   0.83 0.5   0.19* 0.7   0.21* 
Data are means   SD.  
Table 3: General description of the study population 
 
4.1 DNA damage 
Every individual was investigated with special focus on indications for DNA 
damage such as micronuclei and broken eggs using the BMcyt. Cells with mi-
cronuclei and numbers of micronuclei were reported, since one cell sometimes 
can obtain more than one micronucleus. 
Mean DNA damage in the whole study population presented as the number of 
anomalies per 1000 differentiated cells was 0.27   0.36 for cells with micronu-
clei, 0.32  0.43 for the number of micronuclei and 0.60   0.59 for broken eggs. 
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4.1.1 DNA damage in Gilbert´s Syndrome and Controls 
Subjects were divided into the GS or control group according to the level of un-
conjugated bilirubin which was detected by HPLC (for further information see 
the diploma thesis by Katharina Marisch “The DNA protecting effect of unconju-
gated bilirubin”) [Marisch, 2011]. UCB levels were defined for GS group as >1 
mg/dL (17.1 µmol/L and for the control group as <1 mg/dL (17.1 µmol/L). Re-
sults are shown in Table 4. 
 
 Gilbert´s Syndrome Controls p-Value 
Number 45 39  
MNC 0.25  0.36 0.29   0.38 0.607 
MN 0.28   0.41 0.34   0.46 0.590 
BE 0.53   0.50 0.61   0.63 0.619 
BNC 11.50  4.77 11.60   4.39 0.918 
CC/KR 9.85   5.51 9.83   5.18 0.986 
KL 45.35   55.01 31.43   31.63 0.265 
P 1.16   0.87 1.17   0.89 0.948 
Data are means   SD. 
Table 4: DNA damage in GS and control 
 
Between GS and control group no significant results were obtained. However, a 
16 % lower mean in the number of cells with micronuclei as well as a 14 % 
lower mean in the number of micronuclei was seen in GS group compared to 
controls. Furthermore, the latter had a 31 % higher number of karyolytic cells 
than subjects with GS (Figure 14). 
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Figure 14: DNA damage in GS and control 
 
Significantly lower levels of DNA damage were expected in subjects with Gil-
bert´s Syndrome due to elevated levels of unconjugated bilirubin and its there-
fore proposed antioxidative potential. However, insignificantly lower numbers (in 
%) of biomarkers for genotoxicity in GS were noted, which contributes to car-
dioprotective effects of UCB as reported in literature.  
For the first time a study like this was conducted investigating the effects of in-
creased bilirubin levels towards DNA damage by using the Buccal Micronucleus 
Cytome Assay. Therefore, a comparison of the obtained results with existing lit-
erature is not possible. Further research is needed to gain more information on 
possible effects of bilirubin on DNA stability. 
The ranges of micronuclei were within 0.5 – 2.5 MN/ 1000 differentiated cells in 
both GS and control group which goes along with other reports [Thomas et al., 
2009].  
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Thomas et al., 2009 furthermore report that among other factors smoking status 
and age contribute to higher levels of oxidative stress. Most of the participants 
in the study were relatively young and all were non-smokers (up to 5 cigarettes). 
A low level of oxidative stress was therefore assumed in both groups [Thomas 
et al., 2009]. 
What supports this assumption is that results from the thesis by Alice Petschnig 
“Einfluss einer Ernährungsintervention auf das Auftreten von Mikrokernen in 
Mundschleimhautzellen von Typ II-Diabetikern“ showed significant differences 
in the number of broken eggs between former smokers and non-smokers. Ex- 
smokers obtained higher numbers of this biomarker (p= 0.02). This may con-
tribute to the sensitivity of the method and to the quality of the analysis 
[Petschnig, 2011].  
Further results of the mentioned thesis showed that with increased HbA1c lev-
els ( 7.01 %) the number of pyknotic cells rises as well. HbA1c is the main 
marker for evaluating long-term blood sugar regulation and levels exceeding 7 
% are indicative of diabetes. A combination of already established biomarkers 
like HbA1c and biomarkers measured in the BMcyt could be supportive in esti-
mating health risks. 
A study by Dhillon et al., 2004 showed that buccal cells have a shorter turnover 
than lymphocytes and a less active DNA repair system what might indicate a 
higher sensitivity for detection of DNA damage [Dhillon et al., 2004]. 
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4.1.2 DNA damage considering bilirubin tertiles 
Subjects were divided into tertiles with unconjugated bilirubin levels ranging 
from lowest to 11.12 µmol/L, from 11.29 to 20.69 µmol/L and from 20.86 µmol/L 
to the highest concentration. Classification into tertiles aimed to get more results 
concerning bilirubin concentration and DNA damage. 
 
 Tertile1:     
11.12 µmol/L 
Tertile2:  
11.29-20.69 
µmol/L 
Tertile3:  
20.86 µmol/L 
 
p-Value 
Number 33 34 33  
MNC 0.33  0.40 0.24   0.36 0.24   0.33 0.612 
MN 0.41   0.50 0.28   0.39 0.27   0.38 0.503 
BE 0.70   0.65 0.62   0.62 0.45   0.47 0.277 
BNC 11.68   3.99 11.44   4.92 12.34   4.93 0.714 
CC/KR 9.81   4.75 9.22   5.48 9.93   6.01 0.848 
KL 36.64  40.18 51.14   67.08 36.19   31.32 0.367 
P 1.29   0.88 1.26   1.05 1.13   0.83 0.770 
Data are means   SD. 
Table 5: DNA damage represented in bilirubin tertiles 
 
No significant differences were obtained between the tertiles, even though one 
might see higher levels of DNA damage in subjects with lowest UCB concentra-
tions (Figure 15). 
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Figure 15: DNA damage represented in bilirubin tertiles 
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4.1.3 Factors influencing DNA damage 
Gender 
Data from the 70 male and 30 female subjects in the study were analyzed in or-
der to find differences between both sexes (Table 6). 
 
 Men Women p-Value 
Number 70 30  
MNC 0.30  0.37 0.20   0.33 0.182 
MN 0.34  0.42 0.27   0.45 0.315 
BE 0.63  0.60 0.52   0.56 0.346 
BNC 12.07   4.49 11.22   4.91 0.401 
CC/KR 9.24   5.35 10.60   5.45 0.249 
KL 35.80  42.26 52.29   60.19 0.088 
P 1.23  0.93 1.23   0.93 0.977 
Data are means   SD.  
Table 6: Influence of gender on DNA damage 
 
No significant differences were discovered for parameters signalling DNA dam-
age. However, when looking at mean values female subjects show fewer 
anomalies for almost all parameters. They had 33 % less cells with micronuclei, 
21 % less micronuclei, 17 % less broken eggs and 7 % less BNC. A trend (p= 
0.088) for less karyolysis in men was determined (see also Figure 16).  
A study conducted by Fenech et al., 2005 showed that the amount of micronu-
clei in lymphocytes is generally higher in women than in men- and with age lev-
els of MN are increasing progressively in both sexes. This goes along with other 
findings of our study that were described in thesis by Katharina Marisch and 
Maria-Theresia Pappenheim. Already proven for lymphocytes, for buccal epithe-
lial cells clear information on gender differences cannot be given so far [Fenech, 
2005, Marisch, 2011, Pappenheim, 2011]. 
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Figure 16: Gender differences concerning DNA damage 
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Age 
For evaluating the impact of age on the extent of oxidative DNA damage the in-
dividuals were divided into two different groups. Young subjects <30 years and 
old subjects  30 years. The results for mean DNA damage of these subgroups 
are shown in Table 7. 
 
 <30 years  30 years p-Value 
Number 61 39  
MNC 0.33   0.39 0.17   0.29 0.024 
MN 0.39   0.47 0.20   0.34 0.032 
BE 0.73   0.59 0.38   0.51 0.001 
BNC 12.63   4.49 10.54   4.57 0.027 
CC/KR 10.57   4.92 8.21   5.83 0.040 
KL 36.66   44.05 46.29   54.92 0.485 
P 1.33   0.87 1.07   0.98 0.066 
Data are means   SD. 
Table 7: Influence of age on DNA damage 
 
Surprisingly, older individuals showed less numbers of cells with micronuclei, 
micronuclei, broken eggs, binucleated cells, condensed chromatin and karyor-
rhexis. A trend could be noticed for pyknotic cells, which were less in older sub-
jects. Results are furthermore summarized in Figure 17. 
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Figure 17: Influence of age on DNA damage 
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Age subgroups for GS and control 
For more precise information the whole study population was later classified 
into younger (<30 years) and older ( 30 years) Gilbert´s Syndrome and control 
groups. Results are shown in the following figures. 
 
Figure 18: MNC: GS >30 years <GS <30 years (p <0.05) 
Figure 18 shows that GS group ( 30 years) had significantly lower numbers of 
cells with micronuclei compared to GS group (<30 years; p<0.05).  
 
Figure 19: MN: GS >30 years <GS <30 years (p <0.05) 
Figure 19 shows that GS group ( 30 years) had significantly lower numbers of 
micronuclei compared to GS group (<30 years, p<0.05).  
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Figure 20: BE: GS >30 years <GS <30 years (p <0.05) 
Figure 20 shows highly significant (p= 0.001) differences between older GS 
subjects compared to younger GS subjects and as well to younger controls (p= 
0.001). 
 
Figure 21: KR: GS <30 years >GS >30 years (p <0.05) 
The number of karyorrhectic cells was significantly higher (p= 0.042) in older 
GS subjects than in younger GS subjects (Figure 21). 
Allocation into two age groups showed significant differences between older 
and younger subjects and becomes clearer when examining these findings in 
GS. On the contrary Rickes, et al. were not able to determine any age effects in 
persons within 15 and 66 years [Rickes et al., 2010]. The values of MNC and 
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MN might have been influenced by UCB since younger and older controls did 
not show significant differences. 
Due to a broad range of age (20-79 years) participants were divided into two 
age subgroups so that the effects of chronic exposure to elevated bilirubin on 
age related chromosomal damage could be determined. Subjects with GS  30 
years had significantly lower numbers of MNC, MN and BE than the younger 
GS group. These are the first results maintained for chromosomal damage in 
buccal cells in GS that may indicate a protective effect against oxidative-stress 
related actions especially in individuals with chronically (>10 years) and moder-
ately elevated UCB levels. 
GS usually is not developed until adolescence due to an androgen steroid inhi-
bition of the enzymatic bilirubin glucuronidation. This circumstance combined 
with the well documented antioxidative effects of UCB could be an explanation 
for protection from chromosomal damage in older individuals with GS [Muraca 
and Fevery, 1984].  
Karyorrhectic cells by contrast were higher in GS subjects <30 years. KR is in-
dicative for late stages of apoptosis. A possible hypothesis for an increased ap-
pearance of this cell type might be a higher cell division rate in younger people 
that makes elimination of useless or damaged cells necessary.  
Furthermore, bilirubin induces apoptosis in colon cancer cells which is linked to 
a possible chemoprotective role in cancer development in vivo. Buccal and co-
lon cells belong to epithelial lineages and therefore, these new findings in buc-
cal cells might show an important pro-apoptotic role of bilirubin in chemopreven-
tion [Keshavan et al., 2004]. 
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4.1.4 Correlations  
No significant correlations were obtained in the whole study population for UCB 
concentrations and DNA damage.  
Correlations between older GS subjects and parameters of DNA damage with 
Vitamin B12 and folic acid did not show significant results. Folic acid is reported 
to have strong antioxidant potential and therefore might play an important role in 
the development of certain cancers and cardiovascular diseases [Stanger and 
Wonisch, 2012]. 
No investigation on the link between BMcyt-biomarkers and B vitamins has 
been performed yet. However, the results from a study by Stopper et al. showed 
that a combination of folic acid and Vitamin B12 was effective in lowering ho-
mocystein levels and numbers of MN in lymphocytes [Stopper et al., 2008].  
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5 CONCLUSION 
The aim of the present study was to determine antigenotoxic effects of bilirubin. 
Moreover, an evaluation in individuals with chronically mild hyperbilirubinemia 
(Gilbert´s syndrome) was performed to detect whether this condition leads to a 
better protection against oxidative stress and oxidative stress mediated DNA 
damage. 
In order to assess the antigenotoxic potential of bilirubin, biomarkers for chro-
mosomal damage were measured in subjects with Gilbert´s syndrome and con-
trols. The Buccal Micronucleus Cytome Assay (BMcyt) is a minimally invasive 
method for studying DNA damage, chromosomal instability and cell death. 
Numbers of Micronuclei (MN), cells containing MN (MNC) and broken eggs 
(BE) as well as other parameters like binucleated cells (BN), karyorrhexis (KR), 
condensed chromatin (CC), karyolysis (KL) and pyknosis were evaluated. 
Bilirubin obtains strong antioxidative potential and therefore it was hypothesized 
that results show less DNA damage in subjects with GS compared to controls. 
This assumption could not been proved by performing this study. No significant 
differences for all parameters were found between GS and control group. Fur-
thermore, no significant differences for all parameters were seen when dividing 
the study population into bilirubin tertiles. 
Indeed, when dividing GS and controls into 2 subgroups of age (under and over 
30 years), remarkable differences were discovered. Older GS subjects had sig-
nificantly lower numbers of MN, MNC and BE than younger GS subjects. This 
reflects a better protection from genotoxicity in older individuals since they have 
profited from the chronic state of mild hyperbilirubinemia for a longer period of 
time (>10 years). 
When looking at the total study population age aspects showed similar out-
comes. Older participants had lower numbers of almost every measured pa-
rameter. 
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On the other hand no significant differences have been noticed regarding gen-
der aspects. 
Furthermore, when investigating the impact of folic acid and Vitamin B12 on 
DNA damage, no significant outcomes were obtained. 
To conclude, a variety of different factors that influence biomarkers of oxidative 
DNA damage were investigated using the BMcyt. Influence was given through 
age, gender and also dietary substances like folic acid and Vitamin B12. It was 
not possible to detect the power of antioxidative properties of bilirubin towards a 
chromosomal protective effect in subjects with GS compared to controls. De-
spite all, the presented results could bring up the first indication for future re-
search on people that are accumulating oxidative stress as seen in older par-
ticipants. However, further research is needed for getting a better understanding 
of bilirubins´ antioxidant potential and its impact on DNA damage. 
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6 SUMMARY 
Bile pigments are endogenous compounds that are actively produced in hu-
mans via the heme catabolism. The importance of bilirubin in humans has re-
cently been demonstrated in large epidemiological investigations by protecting 
from cardiovascular events and cancer. However, so far no mechanistic data 
are available on the Buccal Micronucleus Cytome Assay (BMcyt), which is a 
minimally invasive method for studying DNA damage, chromosomal instability 
and cell death in high bilirubinic subjects (Gilbert´s syndrome). 
In this case-control study with cross-sectional design, buccal samples were 
taken from 100 subjects, Gilbert´s syndrome and control. Allocation to the GS 
group required serum unconjugated bilirubin levels  17.1 µmol/L (controls 
<17.1 µmol/L). Buccal cells were collected from both cheeks of the participants. 
The obtained cells were extracted, fixed on slides and stained with light green 
(BMcyt). In addition to Micronuclei (MN) and cells containing MN (MNC) the 
number of other anomalies such as binucleated cells (BNC) and broken eggs 
(BE) as well as karyorrhexis (KR), karyolysis (KL), condensed chromatin (CC) 
and pyknosis (P) was evaluated.  
It was hypothesized that subjects with increased UCB levels are better pro-
tected better against DNA damage. Results showed that there was no signifi-
cant difference for all parameters between the GS and control group. However, 
when considering the age impact it was observed that BE (p<0.05) as well as 
MN and MNC (p <0.05) were lowest in the older GS group (subjects older than 
30 years of age). 
For the first time buccal cell damage was investigated regarding the bilirubin 
status in human subjects. Results showed that with increasing age the protec-
tive effects of bilirubin lead to less MN, MNC and BE which exhibits a first 
mechanistic prove of cancer protection by long-term elevated bilirubin levels in 
humans. 
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Nevertheless, only little information on the impact of bilirubin concentrations on 
DNA damage is available. Further research needs to be done for a better un-
derstanding of bilirubins´ protective effects, especially in risk groups of oxidative 
stress.  
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7 ZUSAMMENFASSUNG 
Bei Gallenfarbstoffen handelt es sich um endogen produzierte Verbindungen, 
die im Menschen aktiv während des Häm-Abbaus produziert werden. Die Rele-
vanz von Bilirubin wurde kürzlich durch große epidemiologische Untersuchun-
gen festgestellt, die schützende Effekte auf kardiovaskuläre Erkrankungen und 
Krebs hervorhoben. Bis dato gibt es noch keine aussagekräftigen Daten für den 
Mikrokerntest in Mundschleimhautzellen (BMcyt), welcher eine minimal invasive 
Methode zur Feststellung von DNA-Schäden, chromosomaler Instabilität und 
Zelltod bei Personen mit erhöhten Bilirubinspiegeln (Gilbert´s syndrome) dar-
stellt. 
In dieser Fall-Kontroll-Studie mit Querschnittscharakter wurden Mundschleim-
hautzellen von 100 Teilnehmern, die entweder der Gilbert oder der Kontroll-
gruppe entsprachen, entnommen. Eine Zuweisung in die GS-Gruppe erforderte 
Werte von unkonjugiertem Bilirubin im Serum von  17.1 µmol/L (Kontrollen 
<17.1 µmol/L). 
Die Mundschleimhautzellen wurden von beiden Wangeninnenseiten der Teil-
nehmer entnommen. Die gewonnenen Zellen wurden extrahiert, auf Objektträ-
gern fixiert und mit Light Green gefärbt (BMcyt). Zusätzlich zu Mikrokernen 
(MN) und Zellen, die MN enthalten (MNC) wurden die Werte von weiteren 
Anomalien wie Binucleated Cells (BNC), Broken Eggs (BE), Karyorrhexis (KR), 
Karyolyse (KL), Condensed Chromatin (CC) und Pxknose (P) festgehalten. 
Es wurde angenommen, dass Individuen mit erhöhten UCB-Werten besser vor 
DNA- Schäden geschützt werden. Laut den Ergebnissen konnten keine signifi-
kanten Unterschiede für alle Parameter zwischen GS und Kontrollgruppe fest-
gestellt werden. Allerdings konnte man bei näherer Betrachtung des Altersein-
flusses beobachten, dass sowohl BE (p<0.05), als auch MN und MNC (p<0.05) 
in geringster Häufigkeit in der ältesten Gruppe auftraten (Teilnehmer älter als 30 
Jahre). 
Zum ersten Mal wurden Zellschäden in der Mundschleimhaut herangezogen um 
Rückschlüsse in Bezug auf den Bilirubinstatus in menschlichen Probanden zu 
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ziehen. Die Ergebnisse zeigten, dass mit zunehmendem Alter die schützenden 
Effekte von Bilirubin zum Tragen kommen, indem eine verminderte Anzahl an 
MN, MNC und BE festzustellen war. Dies stellt einen ersten mechanistischen 
Beweis für krebsschützende Effekte durch langzeitlich erhöhte Bilirubinspiegel 
im Menschen dar.  
Nichtsdestotrotz gibt es nur sehr wenig Information bezüglich des Einflusses 
von Bilirubin auf DNA- Schäden. Es ist notwendig, weitere Untersuchungen 
durchzuführen, um ein besseres Verständnis der schützenden Effekte von Bili-
rubin zu erhalten, im speziellen für Risikogruppen die oxidativem Stress ausge-
setzt sind. 
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